Excreção de zinco na urina de indivíduos com síndrome metabólica em uso de terapias anti-hipertensivas

Abstract

Introduction: The pathophysiological abnormalities that are part of the metabolic syndrome can lead to an increase in zincuria, especially during the use of antihypertensives. Objective: To evaluate the zincuria of individuals with metabolic syndrome undergoing antihypertensive therapy. Method: We selected 34 adult and elderly individuals diagnosed with metabolic syndrome. Subjects were divided into two groups: monotherapy and combination therapy, according to the use of antihypertensives. Anthropometric measurements and biochemical analyzes were performed. Zinc intake was evaluated by means of two 24-hour reminders. The 24h urine zinc determinations were performed by atomic absorption spectrophotometry. Results: Individuals had a mean age of 47-51 years, with a predominance of female in both groups. In the monotherapy individuals group, angiotensin receptor blockers and beta-adrenergic blockers (both n = 6; 33, 30%) were predominant and in the combination therapy group combinations of angiotensin receptor blockers and diuretic (n= 7.43.80%). Zinc values in urine 24h did not differ significantly between groups (p = 1,000). Hyperzincuria was recorded in 22.22% of individuals on monotherapy and 14.29% of individuals on combination therapy. Individuals on monotherapy and combination therapy had, respectively, an average zinc intake of 6.5 (2.59) and 6.3 (3.87) mg / day, respectively, with no statistical significance between groups (p = 0.841). Statistically significant (all p <0.05) correlations were observed between dietary zinc and zincuria in the monotherapy group (Rs = 0.527, p = 0.025) and triglycerides in the combination therapy group (Rs = 0.582, p = 0.037). Conclusion: There was no alteration of the zincuria as a function of the antihypertensive therapy used, however the individuals of the monotherapy group presented a higher frequency of hyperzincuria.